Stockscreener 앱 받기
14.91
1.08%
0.16
시장 영업 전:
14.16
-0.75
-5.03%
전일 마감가:
$14.75
열려 있는:
$13.81
하루 거래량:
3.20M
Relative Volume:
1.31
시가총액:
$2.30B
수익:
$10.73M
순이익/손실:
$-455.74M
주가수익비율:
-4.1919
EPS:
-3.5569
순현금흐름:
$-502.70M
1주 성능:
-79.55%
1개월 성능:
-79.50%
6개월 성능:
-68.43%
1년 성능:
-51.34%
1일 변동 폭
$13.81
$15.51
1주일 범위
$13.06
$72.98
52주 변동 폭
$13.06
$73.06
어비디티 바이오사이언스 Stock (RNA) Company Profile
명칭
Avidity Biosciences Inc
전화
858-401-7900
주소
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
14.91 | 11.25B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Roth Capital | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Bernstein | Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-06-11 | 개시 | Raymond James | Strong Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
Novartis completes $12 billion acquisition of Avidity Biosciences - Indian Pharma Post
Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off - Trefis
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month LowHere's What Happened - MarketBeat
Novartis completes $12 billion Avidity Biosciences acquisition By Investing.com - Investing.com Canada
Atrium Arises From Novartis’s Avidity Buyout - Citeline News & Insights
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger - Yahoo Finance
Merger cashout for Avidity Biosciences (RNA) director Simona Skerjanec - Stock Titan
Avidity Biosciences (RNA) CLO disposes stock, options in Novartis merger - Stock Titan
[Form 4] Avidity Biosciences, Inc. Insider Trading Activity - Stock Titan
Merger cash-out: Avidity Biosciences (RNA) officer’s options and shares disposed - Stock Titan
Novartis buyout: Avidity Biosciences (NASDAQ: RNA) director’s equity cashed out - Stock Titan
Avidity Biosciences (RNA) CTO equity disposed in $72 Novartis merger - Stock Titan
Avidity Biosciences shareholders approve merger with Novartis By Investing.com - Investing.com Australia
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA - BioPharma Dive
Operating expenses (excl. COGS) of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Atrium Tx launches with Avidity's RNA ticker and cardio assets - bioworld.com
Avidity-Novartis deal spins out Atrium Therapeutics - The Pharma Letter
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates - Fierce Biotech
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's What Happened - MarketBeat
Novartis completes acquisition of Avidity Biosciences - TipRanks
Avidity Biosciences Completes Merger and Plans Nasdaq Delisting - TipRanks
[POSASR] Avidity Biosciences, Inc. SEC Filing - Stock Titan
As Novartis deal closes, Avidity's rare heart disease spinout launches with $270M - Endpoints News
Novartis (NVS) Completes Acquisition of Avidity Biosciences - GuruFocus
Novartis Completes Acquisition of Avidity Biosciences - marketscreener.com
Novartis completes acquisition of Avidity Biosciences; shares to be delisted from Nasdaq - Investing.com
Novartis Closes $12 Billion Acquisition of Avidity Biosciences - marketscreener.com
Avidity Biosciences Ends ATM Sales Agreement With TD Securities Following Novartis Merger Close - TradingView
Avidity Biosciences Inc (RNAM-Q) Stock Price and News - The Globe and Mail
New RNA drugmaker launches with $270M for rare cardiomyopathies - Stock Titan
Novartis completes $12 billion Avidity Biosciences acquisition - Investing.com
Why Is Avidity Biosciences Stock (RNA) Down Today? - TipRanks
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy - Novartis
Avidity Biosciences (RNAM) Peg Ratio (TTM) - Zacks Investment Research
S&P 500 Futures Decline In Premarket Trading; Avidity Biosciences, Duolingo Lag - 富途牛牛
S&P 500 Futures Decline in Premarket Trading; Avidity Biosciences, Duolingo Lag - Barron's
Avidity Biosciences, Inc. $RNA Shares Bought by JPMorgan Chase & Co. - MarketBeat
Why Avidity Biosciences Shares Are Sliding Now - TipRanks
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - BioSpace
Avidity Shareholders Approve Novartis Merger and Spin-Off - TipRanks
Avidity Biosciences shareholders approve merger with Novartis - Investing.com
Avidity Biosciences (RNA) investors approve Novartis merger and Atrium spin-off - Stock Titan
One-year Duchenne study ties treatment to near-normal creatine kinase levels - Stock Titan
Cash from financing activities of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Promising Medical Stocks To Follow TodayFebruary 26th - MarketBeat
Promising Pharmaceutical Stocks To Follow NowFebruary 26th - MarketBeat
Avidity Biosciences, Inc. Cash Flow – NASDAQ:RNAM - TradingView
Avidity Biosciences, Inc. Balance Sheet – NASDAQ:RNAM - TradingView
Avidity Biosciences, Inc. Financial Statements – NASDAQ:RNAM - TradingView
Net income of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Avidity Biosciences, Inc. Revenue Breakdown – NASDAQ:RNAM - TradingView
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.90%
2.73%
자본화:
|
볼륨(24시간):